PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.25%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.09%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
6.66%
Gross profit growth of 6.66% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
45.88%
EBIT growth exceeding 1.5x Medical - Pharmaceuticals median of 0.14%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
51.13%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 1.78%. Joel Greenblatt would see if unique processes drive exceptional profitability.
46.91%
Net income growth of 46.91% while Medical - Pharmaceuticals median is zero. Walter Schloss might see potential if moderate gains can keep rising.
46.89%
EPS growth of 46.89% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
46.89%
Diluted EPS growth of 46.89% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could improve over time.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.11%. Seth Klarman would see a relative advantage if others are diluting.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
68.51%
10Y revenue/share CAGR 1.25-1.5x Medical - Pharmaceuticals median of 50.88%. Mohnish Pabrai would see if consistent reinvestment or product expansions drive this gap.
64.78%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 13.59%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
35.69%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 6.85%. Joel Greenblatt might see a short-term competitive advantage at play.
100.00%
OCF/share CAGR of 100.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
202.11%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 0.90% over a decade. Joel Greenblatt might see a standout compounder of earnings.
95.22%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 3.12%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
40.35%
3Y net income/share CAGR of 40.35% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a small advantage that can be scaled further.
201.46%
Equity/share CAGR of 201.46% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
125.07%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 3.03%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
58.34%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 6.84%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-47.90%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-6.06%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
1.11%
We expand assets while Medical - Pharmaceuticals is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
3.35%
Positive BV/share change while Medical - Pharmaceuticals median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
-4.77%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
-1.60%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.